Open Payments

Beaumont Health - Grosse Pointe

Type
Teaching hospital
Where
Grosse Pointe, MI
Medicare CCN
230089
Received
$1,524,211 in 282 records, 2025 ($209,719 general, $1,314,491 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment59$209,719
2025Research payment223$1,314,491

By company

CompanyRecordsAmountYears
Boehringer Ingelheim Pharmaceuticals, Inc.24$281,6322025
United Therapeutics Corporation42$235,3572025
PFIZER INC.42$153,2862025
Imperative Care, Inc3$141,5052025
Boston Scientific Corporation20$100,2152025
ModernaTX, Inc.2$97,1842025
AngioDynamics, Inc.1$60,0002025
Janssen Research & Development, LLC16$56,6322025
Intuitive Surgical Operations, Inc.3$55,6222025
Elekta Limited1$54,2502025
Medical Device Business Services, Inc.2$41,9492025
Stryker Corporation10$39,7212025
VB Spine LLC1$28,3872025
IRONWOOD PHARMACEUTICALS, INC14$24,9542025
Biosense Webster, Inc.3$23,2992025
Ipsen Pharma SAS58$18,0522025
Alnylam Pharmaceuticals Inc.3$16,7502025
Becton, Dickinson and Company1$16,6672025
SI-BONE, INC.4$15,7502025
Merck Sharp & Dohme LLC2$10,4212025
Abbott Laboratories6$9,0162025
Novartis Pharmaceuticals Corporation3$8,0812025
National Marrow Donor Program3$7,5102025
Providence Medical Technology, Inc.2$6,3002025
GE HEALTHCARE2$4,7222025
KLS-Martin L.P.3$4,5032025
Teleflex LLC1$2,6402025
BridgeBio Pharma, Inc.3$2,5002025
Novo Nordisk Inc1$1,5002025
Cook Incorporated1$1,5002025
Neurocrine BioSciences, Inc.1$1,2502025
UCB, Inc.1$1,2502025
KARL STORZ Endoscopy-America1$1,0002025
Eli Lilly and Company1$5112025
Fisher & Paykel Healthcare Inc1$2892025

By nature of payment

NatureRecordsAmount
Research payment223$1,314,491
Long term medical supply or device loan13$84,940
Space rental or facility fees (teaching hospital only)20$60,643
Compensation for services other than consulting, including serving as faculty or as a speaker at a v11$33,460
Grant10$21,450
Consulting Fee2$4,722
Debt forgiveness3$4,503

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31AngioDynamics, Inc.$60,000Long term medical supply or device loanIn-kind items and servicesNanoKnife Device, Oncology Surgery2025
2025-12-31Stryker Corporation$3,808Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,716Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,716Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$3,716Long term medical supply or device loanIn-kind items and servicesNA Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$2,861Long term medical supply or device loanIn-kind items and servicesSTRYKER Device, INSTRUMENTS2025
2025-12-31Teleflex LLC$2,640Long term medical supply or device loanCash or cash equivalentDEKNATEL Device, SURGICAL2025
2025-12-31Stryker Corporation$1,860Long term medical supply or device loanIn-kind items and servicesSTRYKER Device, INSTRUMENTS2025
2025-12-31Stryker Corporation$1,767Long term medical supply or device loanIn-kind items and servicesRemB Device, INSTRUMENTS2025
2025-12-31Fisher & Paykel Healthcare Inc$289Long term medical supply or device loanIn-kind items and servicesFISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier2025
2025-12-30Imperative Care, Inc$10,400Research paymentCash or cash equivalentSYMPHONY CATHETER Device, VASCULARTHE IMPERATIVE TRIAL: TREATMENT OF ACUTE ISCHEMIC STROKE WITH THE ZOOM REPERFUSION SYSTEM2025
2025-12-30PFIZER INC.$10,370Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-12-24United Therapeutics Corporation$3,785Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-24United Therapeutics Corporation$3,253Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24United Therapeutics Corporation$1,641Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-12-24United Therapeutics Corporation$1,641Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-12-23Intuitive Surgical Operations, Inc.$15,288Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYA prospective multicenter randomized control trial of da Vinci SP Surgical System vs Open Surgery in Nipple Sparing Mast2025
2025-12-17United Therapeutics Corporation$8,561Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-12-17PFIZER INC.$6,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-12-17United Therapeutics Corporation$1,552Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-12-17Janssen Research & Development, LLC$1,435Research paymentCash or cash equivalentA Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-12-17Novartis Pharmaceuticals Corporation$81Research paymentIn-kind items and servicesA Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [2025
2025-12-12Boston Scientific Corporation$70,200Research paymentCash or cash equivalentAblacath Catheter Device, Resolve-AF Clinical TrialRESOLVE AF2025
2025-12-11Boston Scientific Corporation$500GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-12-10United Therapeutics Corporation$6,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-12-08PFIZER INC.$1,400Research paymentCash or cash equivalentXTANDI Drug, ONCOLOGYA RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA2025
2025-12-08Biosense Webster, Inc.$1,050Research paymentCash or cash equivalentAssessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Abla2025
2025-12-03Boehringer Ingelheim Pharmaceuticals, Inc.$11,608Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-12-01Stryker Corporation$3,796Research paymentCash or cash equivalentGAMMA Device, TRAUMA & EXTREMETIESPOST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-20222025
2025-12-01Janssen Research & Development, LLC$125Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2025
2025-11-28Boston Scientific Corporation$2,000GrantIn-kind items and servicesGeneral - Tachy Device, General - Tachy_CRM2025
2025-11-27PFIZER INC.$5,881Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-11-26United Therapeutics Corporation$9,554Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-26United Therapeutics Corporation$1,468Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-26United Therapeutics Corporation$1,468Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-25Boston Scientific Corporation$1,310Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-11-20Alnylam Pharmaceuticals Inc.$15,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMVUTTRA Drug, Genetic Disease2025
2025-11-20PFIZER INC.$3,932Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-11-20KLS-Martin L.P.$1,033Debt forgivenessCash or cash equivalentLEVEL ONE NEURO, MESH, SPECIALTY, TEMPORAL, 3D GRID, NEURO SCREW, 63 MM, T=0.6 MM, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis2025
2025-11-17UCB, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-17BridgeBio Pharma, Inc.$250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-11-15Novartis Pharmaceuticals Corporation$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalentLEQVIO Drug, Cardiology/Vascular Diseases2025
2025-11-14SI-BONE, INC.$340Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2025
2025-11-13KLS-Martin L.P.$1,033Debt forgivenessCash or cash equivalentLEVEL ONE NEURO, MESH, SPECIALTY, TEMPORAL, 3D GRID, NEURO SCREW, 63 MM, T=0.6 MM, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis2025
2025-11-12United Therapeutics Corporation$8,380Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-12United Therapeutics Corporation$4,838Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-11-12United Therapeutics Corporation$4,190Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-11-10Biosense Webster, Inc.$7,249Research paymentCash or cash equivalentAssessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Abla2025
2025-11-03United Therapeutics Corporation$7,344Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-11-01PFIZER INC.$5,044Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-10-30SI-BONE, INC.$5,602Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2025
2025-10-30PFIZER INC.$500Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-10-28Boehringer Ingelheim Pharmaceuticals, Inc.$11,577Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-28Boston Scientific Corporation$1,050Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-10-27Janssen Research & Development, LLC$125Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2025
2025-10-24Intuitive Surgical Operations, Inc.$11,725Research paymentCash or cash equivalentDa Vinci Surgical System Device, SURGERYA prospective multicenter randomized control trial of da Vinci SP Surgical System vs Open Surgery in Nipple Sparing Mast2025
2025-10-22United Therapeutics Corporation$6,507Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-10-22Abbott Laboratories$1,175Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentARCHITECT Device, Core Diagnostics2025
2025-10-21Becton, Dickinson and Company$16,667Research paymentCash or cash equivalentMidline catheter-related thrombosis2025
2025-10-21KARL STORZ Endoscopy-America$1,000GrantCash or cash equivalent2025
2025-10-20Janssen Research & Development, LLC$1,395Research paymentCash or cash equivalentA Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-10-17National Marrow Donor Program$3,980Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-10-17Stryker Corporation$615Research paymentCash or cash equivalentGAMMA Device, TRAUMA & EXTREMETIESPOST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-20222025
2025-10-15BridgeBio Pharma, Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-10-15ModernaTX, Inc.$1,628Research paymentCash or cash equivalentComparing outcomes in COVID-19, RSV, and Influenza infections2025
2025-10-15BridgeBio Pharma, Inc.$250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-10-14PFIZER INC.$5,051Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-10-13Boehringer Ingelheim Pharmaceuticals, Inc.$3,458Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-10-03Boehringer Ingelheim Pharmaceuticals, Inc.$2,339Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$25,844Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$14,187Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-10-01Boehringer Ingelheim Pharmaceuticals, Inc.$3,792Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-29Janssen Research & Development, LLC$1,375Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2025
2025-09-26VB Spine LLC$28,387Research paymentCash or cash equivalentTRITANIUM PL Device, SpineAnterior Cervical Disectomy And Fusion Using The Tritanium C Anterior Cervical Cage For One Or Two-Levels (VB Spine)2025
2025-09-25PFIZER INC.$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-09-23Neurocrine BioSciences, Inc.$1,250Space rental or facility fees (teaching hospital only)Cash or cash equivalentINGREZZA Drug, Neuropsychiatry2025
2025-09-19Janssen Research & Development, LLC$5,010Research paymentCash or cash equivalentA Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-09-19Ipsen Pharma SAS$2,000Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-09-16Boston Scientific Corporation$200Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-09-10United Therapeutics Corporation$2,003Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-09-08Boehringer Ingelheim Pharmaceuticals, Inc.$7,854Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-05Janssen Research & Development, LLC$272Research paymentCash or cash equivalentA Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv2025
2025-09-04Boehringer Ingelheim Pharmaceuticals, Inc.$44,302Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-09-04PFIZER INC.$3,000Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-09-04PFIZER INC.$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE2025
2025-09-04Janssen Research & Development, LLC$1,375Research paymentCash or cash equivalentA Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap2025
2025-09-03Abbott Laboratories$1,275Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentARCHITECT Device, Core Diagnostics2025
2025-09-01Boehringer Ingelheim Pharmaceuticals, Inc.$2,000Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-08-30PFIZER INC.$9,525Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-08-27United Therapeutics Corporation$4,006Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-08-27United Therapeutics Corporation$2,801Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-08-27PFIZER INC.$1,666Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-08-26Boston Scientific Corporation$1,390Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-08-26Merck Sharp & Dohme LLC$250Space rental or facility fees (teaching hospital only)Cash or cash equivalentVERQUVO Drug, CARDIOVASCULAR2025
2025-08-21Boehringer Ingelheim Pharmaceuticals, Inc.$12,499Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-08-21IRONWOOD PHARMACEUTICALS, INC$793Research paymentCash or cash equivalentC3300-2012025
2025-08-20Janssen Research & Development, LLC$4,970Research paymentCash or cash equivalentA Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR2025
2025-08-19IRONWOOD PHARMACEUTICALS, INC$297Research paymentCash or cash equivalentC3300-2012025
2025-08-13ModernaTX, Inc.$95,556Research paymentCash or cash equivalentComparing outcomes in COVID-19, RSV, and Influenza infections2025
2025-08-11Boehringer Ingelheim Pharmaceuticals, Inc.$14,200Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-11Boehringer Ingelheim Pharmaceuticals, Inc.$250Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025
2025-08-09PFIZER INC.$5,044Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-08-08Ipsen Pharma SAS$1,989Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-08-08Ipsen Pharma SAS$1,881Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-08-06GE HEALTHCARE$2,361Consulting FeeCash or cash equivalent2025
2025-08-04Boehringer Ingelheim Pharmaceuticals, Inc.$21,331Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-08-04PFIZER INC.$4,159Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM2025
2025-07-29PFIZER INC.$3,925Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-07-28Janssen Research & Development, LLC$10,706Research paymentCash or cash equivalentA Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv2025
2025-07-24IRONWOOD PHARMACEUTICALS, INC$5,740Research paymentCash or cash equivalentC3300-2012025
2025-07-24IRONWOOD PHARMACEUTICALS, INC$493Research paymentCash or cash equivalentC3300-2012025
2025-07-24IRONWOOD PHARMACEUTICALS, INC$160Research paymentCash or cash equivalentC3300-2012025
2025-07-23United Therapeutics Corporation$14,632Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-23United Therapeutics Corporation$3,253Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-07-23National Marrow Donor Program$2,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-07-22Boston Scientific Corporation$1,180Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-07-15IRONWOOD PHARMACEUTICALS, INC$1,200Research paymentCash or cash equivalentC3300-2012025
2025-07-15IRONWOOD PHARMACEUTICALS, INC$800Research paymentCash or cash equivalentC3300-2012025
2025-07-15Eli Lilly and Company$511Research paymentIn-kind items and servicesEMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI2025
2025-07-14Medical Device Business Services, Inc.$36,056Research paymentCash or cash equivalentVIVIGEN MIS DELIVERY SYSTEM Device, Spine TraumaClinical Outcomes Associated with the use of ViviGen in Conjunction with Posterolateral Fusion for the Treatment of Lumb2025
2025-07-10PFIZER INC.$3,081Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-07-09United Therapeutics Corporation$6,372Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-09United Therapeutics Corporation$5,000Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-09United Therapeutics Corporation$3,000Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-09United Therapeutics Corporation$1,377Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-09United Therapeutics Corporation$200Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr2025
2025-07-08United Therapeutics Corporation$23,148Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseAn Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis2025
2025-07-08United Therapeutics Corporation$3,110Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-07-02Imperative Care, Inc$36,765Research paymentCash or cash equivalentSYMPHONY CATHETER Device, VASCULARTHE IMPERATIVE TRIAL: TREATMENT OF ACUTE ISCHEMIC STROKE WITH THE ZOOM REPERFUSION SYSTEM2025
2025-06-30Ipsen Pharma SAS$160Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$160Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$131Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$131Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$120Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$120Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$75Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$52Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$52Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$50Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$50Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$41Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$41Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$22Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-30Ipsen Pharma SAS$22Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-06-28PFIZER INC.$12,044Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-06-25United Therapeutics Corporation$5,683Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-06-24Boehringer Ingelheim Pharmaceuticals, Inc.$6,663Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-06-20Janssen Research & Development, LLC$272Research paymentCash or cash equivalentA Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv2025
2025-06-19PFIZER INC.$500Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-06-17Boston Scientific Corporation$990Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-06-13PFIZER INC.$6,725Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-06-13SI-BONE, INC.$5,622Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2025
2025-06-13PFIZER INC.$2,119Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-06-11United Therapeutics Corporation$2,592Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-06-05PFIZER INC.$500Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT2025
2025-06-04Boston Scientific Corporation$5,000GrantCash or cash equivalentGeneral - Structural Heart Device, General - Structural Heart_IC2025
2025-06-04Boston Scientific Corporation$2,000GrantIn-kind items and servicesGeneral - Therapies Device, General - Therapies_EP2025
2025-06-04Boston Scientific Corporation$2,000GrantIn-kind items and servicesGeneral - Therapies Device, General - Therapies_EP2025
2025-06-04Boston Scientific Corporation$2,000GrantIn-kind items and servicesGeneral - Therapies Device, General - Therapies_EP2025
2025-06-01Boehringer Ingelheim Pharmaceuticals, Inc.$24,873Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYAn open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi2025
2025-05-28PFIZER INC.$3,000Research paymentCash or cash equivalentNURTEC ODT Drug, PAINPHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM2025
2025-05-27Boston Scientific Corporation$1,425Research paymentCash or cash equivalentClinical Trial Product Device, Clinical Trial Product_ICCHAMPION-AF2025
2025-05-27PFIZER INC.$1,050Research paymentCash or cash equivalentXTANDI Drug, ONCOLOGYA RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA2025
2025-05-21United Therapeutics Corporation$9,016Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-21Ipsen Pharma SAS$147Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$147Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$147Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$147Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$147Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$147Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$51Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$51Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$51Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$51Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$51Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-21Ipsen Pharma SAS$51Research paymentCash or cash equivalentDysport Drug, NeurologyA Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety2025
2025-05-20Janssen Research & Development, LLC$2,992Research paymentCash or cash equivalentA Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv2025
2025-05-12PFIZER INC.$1,500Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAMAX Drug, CARDIOVASCULAR2025
2025-05-09Elekta Limited$54,250Research paymentCash or cash equivalentELEKTA MEDICAL LINEAR ACCELERATOR Device, LINAC SOLUTIONS (LINAC)Spot-Scanning Proton Arc Therapy2025
2025-05-09PFIZER INC.$5,425Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-05-07United Therapeutics Corporation$4,614Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-07United Therapeutics Corporation$1,468Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-05-06PFIZER INC.$6,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE2025
2025-05-01IRONWOOD PHARMACEUTICALS, INC$6,743Research paymentCash or cash equivalentC3300-2012025
2025-04-28PFIZER INC.$6,000Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalentVYNDAQEL Drug, CARDIOVASCULAR2025
2025-04-25National Marrow Donor Program$1,530Compensation for services other than consulting, including serving as faculty or as a speaker at a vCash or cash equivalent2025
2025-04-17Janssen Research & Development, LLC$8,432Research paymentCash or cash equivalentA Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv2025
2025-04-17IRONWOOD PHARMACEUTICALS, INC$2,534Research paymentCash or cash equivalentC3300-2012025
2025-04-11SI-BONE, INC.$4,185Research paymentCash or cash equivalentIFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTIONSILVIA2025
2025-04-09Boehringer Ingelheim Pharmaceuticals, Inc.$9,431Research paymentCash or cash equivalentJASCAYD Drug, RESPIRATORYA double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w2025
2025-04-09United Therapeutics Corporation$864Research paymentCash or cash equivalentTYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung DiseaseA Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj2025
2025-04-09Abbott Laboratories$435Long term medical supply or device loanIn-kind items and servicesALINITY M Device, Molecular Diagnostics2025
2025-04-09Abbott Laboratories$123Long term medical supply or device loanIn-kind items and servicesALINITY M Device, Molecular Diagnostics2025
2025-04-04Stryker Corporation$13,865Research paymentCash or cash equivalentGAMMA Device, TRAUMA & EXTREMETIESPOST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-20222025
2025-04-03Alnylam Pharmaceuticals Inc.$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentAMVUTTRA Drug, Genetic Disease2025
2025-04-01PFIZER INC.$3,450Research paymentCash or cash equivalentVELSIPITY Drug, INFLAMMATION;PAINAN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WI2025
2025-04-01PFIZER INC.$1,320Research paymentCash or cash equivalentVELSIPITY Drug, INFLAMMATION;PAINAN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WI2025
2025-03-28PFIZER INC.$6,201Research paymentCash or cash equivalentPREVNAR 20 Biological, VACCINESA PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A2025
2025-03-25Janssen Research & Development, LLC$9,619Research paymentCash or cash equivalentA Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv2025
2025-03-25PFIZER INC.$3,000Research paymentCash or cash equivalentVELSIPITY Drug, INFLAMMATION;PAINAN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WI2025

The latest 200 records of 282.

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Wayne CountyGrosse Pointe city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Grosse Pointe, MI, county Wayne County, MI, state Michigan; placed by its city name.

MeasurePlace (city or town)
Grosse Pointe, MI
County
Wayne County, MI
State
Michigan
Population B010035,5411,772,25910,077,761
Population, 2020 census P15,6781,793,56110,077,331
Median age B0100243.837.940.2
Under 18 B0100126.6%23.6%21.2%
65 and over B0100123.2%16.6%18.6%
Households B110012,211700,5914,076,369
Foreign born B050027.8%10.3%7.2%
Median household income B19013$158,853$60,539$72,875
Median family income B19113$180,357$79,522$93,357
Per capita income B19301$86,088$34,906$40,735
Poverty rate B170012.8%20.8%13.2%
Unemployment rate B230254.3%8.7%5.7%
Civilian labor force B230252,769828,8385,018,449
Mean commute (minutes) B0801324.424.724.2
Bachelor's degree or higher B1500373.1%27.6%32.4%
Housing units B250012,452801,0834,622,236
Owner-occupied B2500385.9%64.8%73.2%
Renters B2500314.1%35.2%26.8%
Median home value B25077$436,800$178,500$231,600
Median gross rent B25064$1,725$1,132$1,129
White, not Hispanic B0300291.0%47.9%72.4%
Black B030021.5%36.6%13.1%
Hispanic or Latino B030023.1%6.9%5.9%
Asian B030021.0%3.7%3.4%
American Indian and Alaska Native B030020.1%0.2%0.3%

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Grosse Pointe, MI.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.